Get the latest news, insights, and market updates on KYTX (Kyverna Therapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
3 Promising Penny Stocks With Market Caps Under $2B
As the United States stock market reaches record highs, investors are keenly watching for opportunities that align with the current economic landscape. Amid expectations of potential interest rate cuts, some investors are turning their attention to penny stocks—an investment area that, despite its outdated moniker, remains relevant today. These smaller or newer companies can offer unique value propositions and growth potential when backed by strong financials. In this article, we will explore... Sep 10, 2025 - $KYTX
Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event
KYV-101 has the potential to deliver durable, drug-free, disease-free remission in myasthenia gravis and set a new treatment standard for stiff person syndrome Innovative FDA-aligned KYSA-6 Phase 3 trial design for myasthenia gravis supports clear and rapid path to BLA Webcast today August 28th, at 11 am ET EMERYVILLE, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients w Aug 28, 2025 - $KYTX
Kyverna Therapeutics to Present at Upcoming Investor Conferences in September
EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the following upcoming conferences: 2025 Wells Fargo Healthcare ConferenceFormat: Fireside ChatDate: Wednesday, September 3rd, 2025Time: 11:00 a.m. ET Morgan Stanley 23rd Annual Global Healthcare Aug 25, 2025 - $KYTX
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
Topline data for registrational Phase 2 trial of KYV-101 in stiff person syndrome (SPS) andBLA submission anticipated in 1H 2026 Registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) to include ~60 patients with enrollment to initiate by year-end 2025; interim Phase 2 data expected in Q4 2025 Strong cash position to support upcoming milestones EMERYVILLE, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focus Aug 12, 2025 - $KYTX
Kyverna Appoints New CFO to Guide Next Growth Phase
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) is one of the 11 Best New Penny Stocks to Buy Right Now. On June 30, Kyverna Therapeutics, Inc. (NASDAQ:KYTX) announced that Marc Grasso, M.D. has been appointed as the company’s new Chief Financial Officer (CFO). Before joining Kyverna Therapeutics, Inc. (NASDAQ:KYTX), Dr. Grasso was serving as CFO at Alector, Inc., […] Jul 29, 2025 - $KYTX
Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise
Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that the Company will host a webcast event with Key Opinion Leaders (KOLs) to discuss its neuroimmunology franchise. The event will take place on Thursday, August 28, 2025, from 11:00am to 1:30pm ET. Jul 29, 2025 - $KYTX
Undervalued Opportunities: Penny Stocks Worth Watching In July 2025
Over the past year, the United States market has seen a 13% rise, although it remained flat over the last week, with earnings forecasted to grow by 15% annually. In this context of steady growth and future potential, identifying stocks with strong financial health becomes crucial for investors seeking opportunities. Penny stocks, though an older term in today's financial lexicon, still represent smaller or newer companies that might offer significant value when backed by solid fundamentals. Jul 11, 2025 - $KYTX
Kyverna Therapeutics Announces Appointment of New Chief Financial Officer
Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced the appointment of Marc Grasso, M.D., as its Chief Financial Officer (CFO), effective today. Dr. Grasso brings more than 25 years of public company, capital markets, and investment banking management experience to the role. He succeeds Ryan Jones, MBA, who will move to a strategic advisor role to ensure a seamless tra Jun 30, 2025 - $KYTX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple